Is a standard fixed dose of mycophenolate mofetil ideal for all patients?

27Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. A standard fixed dose of 2 g/day of mycophenolate mofetil (MMF), irrespective of total body weight (TBW), is recommended when used in combination with cyclosporine and corticosteroids in renal transplantation. Methods. To determine the optimal MMF dose in a population with wide variation in TBW, steady-state pharmacokinetics of mycophenolic acid (MPA) was performed in 53 Asian (Chinese, Malay, Indian, Eurasian) renal transplant recipients (RTX) receiving MMF [250-1000 mg twice daily (BD)] for at least 3 months. Blood samples were collected at 0, 0.5, 1, 1.5, 2 and 6 h after the MMF dose and total MPA quantified using HPLC. Results. Drug exposure, as evaluated by AUC ss, 0-12, demonstrated a significant positive correlation with TBW-adjusted MMF dose (outliers omitted: r2 = 0.49, P < 0.0005). An AUCss, 0-12 of 45 mg h/l could be attained with an MMF dose of 12 mg/kg BD. Conclusion. This study proposes that MMF should be dosed based on TBW rather than a fixed dose regimen in RTX. © The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Cite

CITATION STYLE

APA

Yau, W. P., Vathsala, A., Lou, H. X., & Chan, E. (2007). Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrology Dialysis Transplantation, 22(12), 3638–3645. https://doi.org/10.1093/ndt/gfm468

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free